Tharimmune appoints clay kahler and gary stetz to its board of directors

Bridgewater, nj / access newswire / april 30, 2025 / tharimmune, inc., (nasdaq:thar) ("tharimmune" or the "company") a clinical-stage biopharmaceutical company focused on developing innovative therapeutics in inflammation & immunology, today announced the appointment of clay kahler and gary stetz to its board of directors, increasing the tharimmune board to nine directors. as reported in a form 8-k filed on april 25, 2025, directors leonard mazur and lynne bui, m.d.
THAR Ratings Summary
THAR Quant Ranking